Stomach

Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours

Retrieved on: 
tisdag, maj 28, 2024
Lung, Bile, Prognosis, Warsaw Stock Exchange, Patent, Pancreatic cancer, Liver, Urine, FDA, Drug development, Prostate, Cancer, Ovary, Kidney, Brain, Breast, URT, Stomach, IVD, Enzyme, Medical imaging

Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock Exchange: URT) biotechnology company specialising in the development of breakthrough technology to detect cancer from urine samples has developed a prototype IVD test for detecting brain tumours.

Key Points: 
  • Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock Exchange: URT) biotechnology company specialising in the development of breakthrough technology to detect cancer from urine samples has developed a prototype IVD test for detecting brain tumours.
  • In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its flagship project PANURI, a test for pancreatic cancer.
  • Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours.
  • In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests.

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Patient, TKI, Pembrolizumab, Glioblastoma, Lung cancer, Non-small-cell lung cancer, Safety, EGFR, NSCLC, RECIST, PRS, Stomach, Cancer, Sarcoma, Abstract, Society, Immunotherapy, PD-L1, CD137, Annual general meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding MCLA-145 and an abstract regarding MCLA-129 at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. Both abstracts can be found on the 2024 ASCO® website.

Key Points: 
  • Both abstracts can be found on the 2024 ASCO® website.
  • “We continue to be proud of our Multiclonics® technology platforms' ability to develop bispecific antibodies for clinical investigation with the potential to impact patients’ lives,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus.
  • Pts treated with the combination of MCLA-145 and pembrolizumab had cancers that either relapsed after PD-(L)1 therapies or were immunotherapy naïve.
  • Poster presentation title: Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14)
    As full presentations become available at the 2024 ASCO® Annual Meeting, they will contemporaneously be available on the Merus website .

Dr. Moustafa Youssef's Byline Article on Transoral Incisionless Fundoplication (TIF) Highlights Breakthrough in Gastroenterology

Retrieved on: 
tisdag, maj 21, 2024
Patient, Nissen fundoplication, Mouth, Risk, Interview, Heartburn, Transoral incisionless fundoplication, Anatomy, Anecdote, Esophagus, Gastroesophageal reflux disease, Quality of life, Stomach, Medical device

Titled "Enhancing Digestive Health: A Breakthrough in Gastroenterology with Transoral Incisionless Fundoplication," Dr. Youssef's article delves into the transformative impact of TIF on patient outcomes and quality of life.

Key Points: 
  • Titled "Enhancing Digestive Health: A Breakthrough in Gastroenterology with Transoral Incisionless Fundoplication," Dr. Youssef's article delves into the transformative impact of TIF on patient outcomes and quality of life.
  • In his article, Dr. Youssef emphasizes the revolutionary nature of TIF in changing the treatment landscape for acid reflux.
  • He underscores the minimally invasive nature of the procedure, which offers patients a safer and more efficient alternative to traditional surgical interventions.
  • Dr. Moustafa Youssef asserts that Transoral Incisionless Fundoplication represents a major advancement in the field of gastroenterology, offering a safe, effective, and minimally invasive solution for the treatment of GERD.

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Retrieved on: 
tisdag, maj 14, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Medical Devices, Research, Surgery, Science, Stomach, MPH, DDW, ASGE, Organization, Meta-analysis, Treatment, University, Woman, Esophageal cancer, FACG, Barrett's esophagus, FACP, FACS, Division, GI, Abstract, Risk factor, Malignancy, Systematic review, Esophagus, Hepatology, Vaccine

Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis

Key Points: 
  • Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis
    Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
    Title: The Tissue Systems Pathology Test Provides Clinically Actionable Risk-Stratification in Patients with Barrett’s Esophagus: A Multicenter U.S. Clinical Experience
    Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
    For more information on the above abstracts and the TissueCypher test, visit Castle at booth 3737; a complete list of Castle’s activities at DDW 2024 can be found at https://info.castlebiosciences.com/ddw2024 .
  • Key events include the following:
    Panel discussion to include: Emmanuel Gorospe, M.D., MPH, FACP, FACG, FASGE, GI medical director at Castle Biosciences; Dan Lister, M.D., FACS, FAFS, surgeon and director of the Arkansas Heartburn Treatment Center, and co-founder and president elect of the American Foregut Society; Dr. Farhan Quader, M.D., interventional gastroenterologist at NorthShore University Hospital in Chicago; Sarah Enslin, PA-C, Division of Gastroenterology and Hepatology at the University of Rochester Medical Center Rochester in New York
    Additionally, Castle is collaborating with several organizations, including the ASGE, Esophageal Cancer Action Network, American Muslim Gastroenterologist Network, American Foregut Society and Women in Endoscopy on various educational and networking events taking place throughout the meeting.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
fredag, maj 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
fredag, maj 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Multimedia, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Retrieved on: 
torsdag, maj 9, 2024
FDA, SOS, Mouth, Cell, Risk, Obstruction, Stomach, Lucid, Collection, Research, Medtronic, Patient, Esophagus, Airway obstruction, Cancer, Medical device

NEW YORK, May 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophageal cell collection device, which it briefly supplied to third-party institutions for their own research studies, has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publication of one of these studies. EsophaCap is not a commercial Lucid product.

Key Points: 
  • In addition, troubling reports of serious device failures have plagued SOS devices for many years, leading to multiple Class II FDA recalls similar to this one.
  • Dr. Aklog added, "In stark contrast, Lucid's EsoCheck® Esophageal Cell Collection Device , with its patent-protected Collect+Protect™ technology, is a modern groundbreaking technology.
  • These detachments were similar to previously-reported detachments of the Cytosponge Cell Collection Device, an SOS manufactured by Medtronic, which led to two Class II FDA recalls, including a June 2023 open global recall , which remains in effect.
  • As the manufacturer of record, Lucid proactively informed the FDA of the reported device failures and concluded that a Class II recall of the EsophaCap SOS was necessary and was made effective as of April 25, 2024.

Knight Therapeutics Reports First Quarter 2024 Results

Retrieved on: 
torsdag, maj 9, 2024
Knight, DLBCL, News, ITP, Health maintenance organization, Hot, Vaginal discharge, Depreciation, Thrombocytopenia, Stomach, Inventory, Collection, Trial of the century, ASCT, Lymphoma, Patient, Acquisition, VVA, IAS, Menopause, Lenalidomide, Absorption, Blue balls, Bookkeeping

Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.

Key Points: 
  • Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.
  • Accounts payable and accrued liabilities: As at March 31, 2024, accounts payable and accrued liabilities were $94,711, an increase of $4,094 or 5%.
  • Cash, cash equivalents and marketable securities: As at March 31, 2024, Knight had $181,859 in cash, cash equivalents and marketable securities, an increase of $20,034 or 12% compared to December 31, 2023.
  • Knight will host a conference call and audio webcast to discuss its first quarter ended March 31, 2024, today at 8:30 am ET.

Peanuts and Peanut Butter Support Women's Health

Retrieved on: 
onsdag, maj 8, 2024
Snack, Mortality, Adolescence, Nutrition, Risk, Mineral, Nutrition and Cancer, PMID, Grain boundary strengthening, Sport, Niacin, Death, American Academy of Pediatrics, PubMed, Parent, Water, INT, Choline, Food, Mother, Neurosurgery, Control, Cancer, Phytosterol, Journal, Peanut, American Heart Association, Deficit spending, Alzheimer's disease, Cyrus the Great, American Academy, Brain, Iron, Randomized controlled trial, Cardiovascular disease, Dementia, Arginine, Zinc, Vitamin, Infant, Infection, Choking, Meta-analysis, Consumer, Health, Research, Taste, Dicarboxylic acid, Food industry, Exercise, Sterling, Lung, Pediatrics, Multimedia, Fruit, Breast milk, Pinterest, Meal, Stomach, Habit, Disease, PubMed Central, Nut, General Population (album), Growth, Dietary supplement

To help women protect their health, The Peanut Institute is sharing information on the benefits that regular consumption of peanuts and peanut butter deliver to females at every stage of life.

Key Points: 
  • To help women protect their health, The Peanut Institute is sharing information on the benefits that regular consumption of peanuts and peanut butter deliver to females at every stage of life.
  • Initially, parents can thin a very small amount of peanut butter or peanut powder with water and mix it into rice cereal.
  • "For example, offering healthy snacks like fresh veggies or fruit paired with peanut butter or peanuts is a great option.
  • For more health news and tasty recipes that include peanuts and peanut butter, visit PeanutInstitute.com or follow Facebook , Twitter , Instagram , LinkedIn and Pinterest .

Private tutors can make the exam season a calmer, mentally healthier time for stressed students

Retrieved on: 
tisdag, maj 7, 2024
Frustration, Brain, Bangladesh Technical Education Board, Learning, Health, Sleep, Procrastination, Stomach, Conference, Parent, Research, Student, Environment, Exercise, Mental health, Headache, Movement, Failure, Tutoring, Music, Child, Mental Health Awareness Month

Expert private tutors can support academic study and exam-readiness while promoting students' mental health with movement, exploration and mentorship.

Key Points: 
  • Expert private tutors can support academic study and exam-readiness while promoting students' mental health with movement, exploration and mentorship.
  • Adam Caller: "Having a full-time private tutor doesn't just lead to outstanding exam results but also gives students the skills and confidence needed to excel in those exams - and the future.
  • Private tutoring for exam preparation, mentorship, and mental health
    Tutors International, with its worldwide network of skilled tutors, offers personalised residential tutoring.
  • More than just helping students succeed academically, private tutors are experienced in keeping students healthy - mentally and physically - so they can face their exams feeling ready and confident.